New York – May 31st, 2019 – Profacgen, as a state-of-the-art protein products and service provider, focusing on providing custom protein services in the biological sciences that enable access to the latest tools, techniques, and expertise with competitive pricing and rapid turnaround time, announced the releases of small molecule-based conjugation services to help our customers develop a new class of therapeutic agents targeting cancers and other difficult-to-treat diseases based on the discovery of PROTAC.
The PROTAC-based drug paradigm uses a protein degradation strategy rather than protein inhibition. This strategy has several advantages, including the potential to target proteins that are currently not drug sensitive using small molecule protein methods. This greatly expands the ability to manufacture drugs for many new, previously inaccessible targets.
Arvinas’ PROTAC platform degrades pathogenic proteins by using the cell’s natural and selective ubiquitin-proteasome system. Like most small molecule drugs, protein degradation does not inhibit proteins like most small molecule drugs, but uses the cell’s natural “garbage removal” process to completely eliminate proteins.
Through a variety of protein targets, Arvinas’ PROTAC platform has demonstrated that transient binding events within certain binding sites and affinities can result in very efficient degradation of the target protein. At present, PROTAC is becoming a promising strategy for proteins such as estrogen-related receptor alpha, cellular retinoic acid binding protein. The key step in PROTAC is to construct heterobifunctional small molecules with two warheads – one to bind to the target protein and the other to recruit E3 ligase.
‘Our services include different modules covering all aspects of PROTAC development, from ligand identification to biological assessment. We encourage customers to choose the individual module that best suits their needs.’ Said Ellen Burns, the marketing director of Profacgen, she also claimed, ‘For the best results, we recommend our one-stop service package to provide unparalleled value and to fully develop your research project from scratch.’
Profacgen provides consumers with innovative protein products and services to greatly enhance experimental performance and promote the development of bio-related research. With a commitment to delivering high-quality data and customer services, Profagen has been extensively working on bioconjugation services and assay development for more than a decade. Profacgen is a well-recognized industry leader with more than 10 years of experience to support worldwide researchers.
Company Name: Profacgen
Contact Person: Ellen Burns
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States